Digipath
CHM Cannabis
Home > Boards > US OTC > Cannabis >

CV Sciences Inc. (CVSI)

CVSI RSS Feed
Add CVSI Price Alert      Hide Sticky   Hide Intro
Moderator: lester12483, AsiaT, ANIA77, Sunblazers, Benjamin Wulf, Deetew
Search This Board: 
Last Post: 12/14/2018 1:38:57 PM - Followers: 532 - Board type: Free - Posts Today: 111

CV Sciences United States OTCMKTS:CVSI Business Cannabidiol - united states

CV Sciences, Inc., incorporated on July 26, 2013, is a life science company. The Company operates in two segments: specialty pharmaceuticals and consumer products. The Company’s specialty pharma business segment is focused on developing and commercializing therapeutics utilizing synthetic Cannabidiol (CBD) across several therapeutic areas. The consumer product business segment is focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.

 

The Company's product candidates utilize synthetic CBD as the active pharmaceutical ingredient. Its product candidates are in preclinical studies. The Company manufactures, markets and sells products containing hemp-derived CBD primarily under its PlusCBD brand. The Company's subsidiaries include US Hemp Oil, LLC, CannaVest Laboratories, LLC, Plus CBD, LLC and CannaVest Europe, GmbH.

The Company focuses on developing and commercializing proprietary prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient and is engaged in the development, manufacturing, marketing and sale of consumer products containing plant-based CBD, which is refined into its own proprietary branded products. CV Sciences initial drug candidate (CVSI-007) is a chewing gum that combines CBD and nicotine, which the Company believes has the potential to effectively treat smokeless tobacco use and addiction. The market for cessation of smokeless tobacco use and addiction is estimated at $2 billion, growing to over $4 billion in the next 5-6 years.

 

CV Sciences, Inc. Issues Letter to Shareholders

 
GlobeNewswireJune 27, 2018
 
 

LAS VEGAS, June 27, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc., (CVSI) (the "Company," "CV Sciences," "our" or "we"), preeminent manufacturer and distributor of the industry-dominating brand of hemp extract products, PlusCBD Oil™, announced today that it has issued a letter to its shareholders, providing an update on the Company’s recent progress and upcoming objectives. 

Highlights of the Letter Include:

  • Summary of its record breaking and profitable first quarter of 2018 which included record revenue, gross profit, cash flow, adjusted EBITDA and net income.
     
    Expansion of the Company’s footprint in the CBD product market with its PlusCBD Oil™ hemp-based CBD products rated #1 in the natural products retailer sales channel.  This market opportunity is forecasted at $2.5 billion by 2022.
     
    Updates on its drug development efforts, its proprietary patent-pending drug candidate (CVSI-007) to treat smokeless tobacco addiction, a $2 billion market opportunity.
     
    Corporate developments that include deleveraging the Company’s balance sheet and positioning for future growth.
     
    Details of CV Sciences’ upcoming annual general meeting (AGM) to be held on August 4, 2018 at the Company’s new San Diego headquarters.
     
    Initiatives for 2018, focusing on operational efficiencies, sales growth, distribution channels, large drug development milestones that include investigational new drug application submission and clinical trials, and uplisting our stock to a major national exchange.

The Company’s Chief Executive Officer, Joseph Dowling, commented, “Our uplist initiative to a major national exchange is an important Company objective. The national exchanges require that a listed company’s stock price trade at certain levels for acceptance. We have included a proposal for shareholder vote at our AGM on August 4, 2018 for a reverse stock split, which has as its sole purpose clearing a pathway for the Company to “uplist” to a major national exchange. The Company will effectuate the reverse split only in connection with an application to uplist to a major exchange, and only if necessary.”  

To read the Letter to Shareholders in full, please visit: https://ir.cvsciences.com

About CV Sciences, Inc.

CV Sciences, Inc. (CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:

Robert Haag
Managing Director
IRTH Communications
CVSI@irthcommunications.com
866-976-4784

 

The Company competes with GW Pharmaceuticals, PLC, Zynerba Pharmaceuticals Inc. and Insys Therapeutics Inc

 

CV Sciences, Inc. Announces Landmark Publication on the Toxicology and Safety Assessment of Base Material of its PlusCBD Oil™ Products

 
GlobeNewswireJune 15, 2018
 
 

LAS VEGAS, June 15, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our” or “we”) announced today the June 7, 2018 publication of the toxicology and safety results of an extract from the base raw materials used in its market leading PlusCBD Oil™ consumer products. The Company contracted respected scientific and regulatory consulting firm, AIBMR Life Sciences, Inc, to conduct the battery of toxicological studies to investigate the safety of oral consumption of the Company’s hemp cannabidiol (CBD) oil and to support a Generally Recognized as Safe (GRAS) Independent Conclusion.

The monumental study entitled, “An Assessment of the Genotoxicity and Subchronic Toxicity of a Subcritical Fluid Extract of the Aerial Parts of Hemp”concluded that the test article was non-mutagenic, non-clastogenic and non-genotoxic. The toxicological assessment is the first known published data of its kind since the 1980 Rosenkrantz et al.’s publication with respect to toxicology data on CBD, Cannabichromene and hashish oil. The battery of GLP/OECD compliant studies is a major contribution in advancement of the science of hemp-derived CBD.

The investment in this toxicological assessment demonstrates CV Sciences’ commitment in furthering the science behind the ingredient. AIBMR’s Chief Scientific Officer, John Endres, ND, comments, “Until today, there have been no comprehensive toxicological safety assessments completed on hemp CBD oil for 38 years. The completion and publication of these safety studies on this ingredient in a peer-reviewed academic journal specializing in toxicology is a monumental step forward in putting competent and reliable science behind a product. The public should applaud this effort as well as the time and expense it required.”

The Company’s Chief Executive Officer, Joseph Dowling, echoed this sentiment. “We are thrilled to advance phytocannabinoid science and are very pleased with the safety results from this landmark study. This is an important milestone in our pursuit of GRAS status,” he remarked. “As an organization, our commitment to safety remains paramount. We look forward to setting the bar for all hemp extract manufacturers in the market and encourage them to conduct similar toxicological assessments on their own base raw materials.”

About CV Sciences, Inc.
CV Sciences, Inc. (CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California.  Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

Video tour of San Diego Office of CVSI.
https://www.facebook.com/pluscbdoil/videos/1974202205985123/

Digipath
CHM Cannabis
CVSI
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVSI News: Departure of US AG and Democratic House Control Improve Prospects for Hemp Industry 11/27/2018 08:45:00 AM
CVSI News: Growing Cannabis Industry Creates Space for New Strategies 11/13/2018 08:45:00 AM
CVSI News: Current Report Filing (8-k) 11/07/2018 03:58:54 PM
CVSI News: Quarterly Report (10-q) 11/07/2018 08:09:14 AM
CVSI News: Industrial Hemp Floodgates Open as CBD Demand Grows 11/06/2018 08:45:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#36187  Sticky Note Response to Robbins Arroyo LLP complaint Deetew 12/04/18 08:45:29 PM
#27902  Sticky Note Fantastic report. Must read. https://www.streetwisereports.com/article/2018/09/ Emerald77 09/24/18 07:39:45 PM
#20309  Sticky Note Please read this BOARD WARNING before you submit IH Admin [Tisha] 08/22/18 12:47:06 PM
#37432   Cvsi only cares about the 007 gum if Hmmmmmm 12/14/18 01:38:57 PM
#37431   Except CVSI of course. Vandalayind 12/14/18 01:34:42 PM
#37430   Find 1 person on this board that is Hmmmmmm 12/14/18 01:32:58 PM
#37429   The "Market" represents the "Masses". If you SweetEquity 12/14/18 01:31:35 PM
#37428   Old: Both product candidates are currently in preclinical studi Vandalayind 12/14/18 01:24:52 PM
#37427   Haha yawn zzzz crickets hiccup burgerburp omg. Hmmmmmm 12/14/18 01:22:58 PM
#37426   Same language 2 years later Carl. Vandalayind 12/14/18 01:20:27 PM
#37425   2015 Filings! Anyone recognize the language in the CashMoneyCarl 12/14/18 01:15:58 PM
#37424   brok9 grow up all right all right 12/14/18 01:14:01 PM
#37423   Both product candidates are currently in preclinical Vandalayind 12/14/18 01:12:03 PM
#37422   2015 Filings! Anyone recognize the language in Vandalayind 12/14/18 01:11:11 PM
#37421   It should be Illegal to Short in OTC. SweetEquity 12/14/18 01:10:48 PM
#37420   In English please. Bokonon9 12/14/18 01:05:02 PM
#37419   M microcappatty 12/14/18 12:59:33 PM
#37418   Shouldn't have got in heavy at this level, Vandalayind 12/14/18 12:54:06 PM
#37417   What is the meaning to mazeltav and the smacman 12/14/18 12:45:42 PM
#37416   $CVSI BOOOM HERE IT IS > https://www.marketwatch.com/press-release MazelTov 12/14/18 12:41:37 PM
#37415   So what should we all do? Dw king 12/14/18 12:36:16 PM
#37414   market nerev wrong is right that is the all right all right 12/14/18 12:33:04 PM
#37413   "The bottom line is, the market's never wrong. Vandalayind 12/14/18 12:25:11 PM
#37412   https://realmoney.thestreet.com/articles/01/07/2016/traders-notebook-market-neve Vandalayind 12/14/18 12:23:36 PM
#37411   cvsi--- story is 17c to 420 in is all right all right 12/14/18 12:14:47 PM
#37410   You are not wrong bearcat 10. It was Chirodoctor 12/14/18 12:11:38 PM
#37409   Vandy. Of course PPS will bleed if nothing smacman 12/14/18 11:40:52 AM
#37408   Oh I agree, trades can be made. Vandalayind 12/14/18 11:25:17 AM
#37407   Holy crap CMC, you really know how to MaxwellE 12/14/18 11:23:34 AM
#37406   Let's just see where share price is come mc73 12/14/18 11:20:14 AM
#37405   Last meaning stock price move? Sell off at CashMoneyCarl 12/14/18 11:18:55 AM
#37404   Yes...Use the 1 year chart....use any chart. Vandalayind 12/14/18 11:12:07 AM
#37403   I agree with Vandy on a lot of CashMoneyCarl 12/14/18 11:10:10 AM
#37402   Message boards. Know Charts in the OTC. Vandalayind 12/14/18 11:05:43 AM
#37401   I see what you are saying. CashMoneyCarl 12/14/18 11:05:37 AM
#37400   I'm not really talking about current share price. Vandalayind 12/14/18 11:00:56 AM
#37399   Is there a How to Trade Stocks for InvestNStocksUS 12/14/18 10:59:18 AM
#37398   Yes 2.93. Vandalayind 12/14/18 10:55:33 AM
#37397   News = POTN intresting. Mark44 12/14/18 10:55:31 AM
#37396   Which coincides with the 200 approximately. CashMoneyCarl 12/14/18 10:54:14 AM
#37395   Otflmao...ha ha ha. Chirodoctor 12/14/18 10:54:12 AM
#37394   These people were not speedy enough to buy TheCapitalist 12/14/18 10:51:47 AM
#37393   Absolutely nothing. Hmmmmmm 12/14/18 10:50:21 AM
#37392   See what looks like a camels hump if Vandalayind 12/14/18 10:48:21 AM
#37391   Why has the bid/ask been wrong at the Bulldog7272 12/14/18 10:46:15 AM
#37390   Crossed 4.6. Looks set to rise higher. TheCapitalist 12/14/18 10:44:50 AM
#37389   In idiot English please? InvestNStocksUS 12/14/18 10:42:51 AM
#37388   P.S. Share price currently headed for another crayon connection. Vandalayind 12/14/18 10:40:06 AM
#37387   Maybe I am dumb? But what does GNC’s Bearcat10 12/14/18 10:37:33 AM
#37386   Shoot. Draw two lines go back 3 years. Vandalayind 12/14/18 10:36:13 AM
#37385   Sure that works. Vandalayind 12/14/18 10:34:54 AM
#37384   Otflmao...ha ha ha. Chirodoctor 12/14/18 10:34:27 AM
#37383   Take one and draw a line connecting all ap17 12/14/18 10:32:21 AM
PostSubject